Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 40

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 40
---
 shares of Common Stock, (ii) 490,534                                                                                 
 shares of Common Stock, held by the Atwood-Edminster Trust dtd 4-2-2000 (the “Trust”), of which Mr. Atwood and                             
 Lynne H. Edminster serve as trustees (iii) 5,080 shares of Common Stock, issuable pursuant to stock options exercisable within 60 days     
 of April 11, 2025 and (iv) shares underlying 11,660 Pre-Funded Warrants held by Mr. Atwood, which is the maximum number of such Pre-Funded 
 Warrants held thereby that may be exercised without exceeding the beneficial ownership limitations set forth therein. Excludes warrants    
 and/or pre-funded warrants held by Mr. Atwood and GVN, LLC (of which Mr. Atwood and Lynne H. Edminster serve as managers, and the sole     
 member is the Trust) that are in excess of the applicable beneficial ownership limitations.                                                |

| (7) | Consists of 5,976 shares of Common Stock issuable pursuant to 
 stock options exercisable within 60 days of April 11, 2025.   |

| (8) | Consists of (i) 59 shares of Common Stock held by Kathleen                                                                          
 LaPorte, (ii) 9,660 shares of Common Stock, held by the Kathleen LaPorte Revocable Trust, of which Ms. LaPorte serves as a trustee, 
 and (iii) 5,976 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of April 11, 2025.             |

| (9) | Consists of 5,976 shares of Common Stock issuable pursuant to 
 stock options exercisable within 60 days of April 11, 2025.   |

| (10) | Consists of 5,040 shares of Common Stock issuable pursuant to 
 stock options exercisable within 60 days of April 11, 2025.   |

Item 13. Certain Relationships and Related Transactions, and Director Independence Other than the compensation agreements and other arrangements described under the sections entitled “ Executive Compensation” and “ Director Compensation” above and the transactions described below, since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which:

| ● | the amount involved exceeded,